Biogenerics Bill From Reps. Eshoo And Barton “Expects” Limits On Substitution
Interchangeability standards that come close to those sought by the Bush administration are contained in follow-on biologics legislation that is expected to be introduced shortly by Rep. Anna Eshoo, D-Calif
You may also be interested in...
Romney Advisor Leavitt Champions Part D As Model For Medicare Reform
As the presumptive architect of Republican presidential candidate Mitt Romney’s transition plan, former HHS Secretary Mike Leavitt would be a strong proponent for modeling future Medicare Parts A and B reforms on the Part D program.
Biosimilar Competition Debate: Must Products Be Interchangable To Generate Savings?
FTC hears arguments on whether the number of competitors, or their pharmacy-level substitutability, drives prices lower.
Follow-On Biologics Bill Could Be Shaped By Waxman/Dingell Fight For House Commerce Cmte.
Chairmanship would give Waxman more leverage to place regulatory flexibility into the biosimilars approval pathway.